Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 7/20 | 0.34 |
| ▸ | CTSS | P25774 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632990 | 0.80 | L3MBTL1 (0.31) | HTTL3MBTL1 | |
| SCHEMBL24312282 | 0.80 | L3MBTL1 (0.49) | APLNRCA1CA2CA7MEN1 | |
| SCHEMBL22380380 | 0.75 | APLNR (0.39) | APLNRAAK1CA1CA2CA7 | |
| SCHEMBL22644353 | 0.73 | APLNR (0.41) | APLNRAAK1CA1CA2CA7 | |
| SCHEMBL20684929 | 0.73 | HTT (0.31) | APLNRHTTL3MBTL1 | |
| SCHEMBL22644354 | 0.72 | APLNR (0.41) | APLNRAAK1CA1CA2CA7 | |
| SCHEMBL2187338 | 0.71 | NPC1 (0.36) | APLNRCA1CA2CA7MEN1 | |
| SCHEMBL3528175 | 0.69 | L3MBTL1 (0.49) | APLNRCA1CA2CA7MEN1 | |
| SCHEMBL29168310 | 0.68 | CA1 (0.39) | APLNRCA1CA2CA7MEN1 | |
| SCHEMBL5169401 | 0.67 | CTSS (0.37) | CA1CA2CA7MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491148-B2 | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2022-11-08 | — | — | US | disclosed |
| EP-3966205-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-16 | — | — | EP | disclosed |
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-12 | — | — | US | disclosed |
| WO-2020225230-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | APLNR 625/4885AAK1 1721/4885CA1 4473/4885 |
| US-11491148-B2 | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases | HDGF, HAVCR2, FABP1 | APLNR 726/4885AAK1 2777/4885CA1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.